Late Breaking Abstract- Comparative Effectiveness of Anti-IL5/5R Versus Anti-IgE in Patients Eligible for Both (FIRE)

被引：1
|
作者：
Ali, Nasloon [1 ]
Lyu, Juntao [1 ]
Newell, Anthony [1 ]
Sadatsafavi, Mohsen [2 ]
Tran, Trung N. [3 ]
Price, David B. [1 ,4 ]
机构：
[1] Observat & Pragmat Res Inst, Singapore, Singapore
[2] Univ British Columbia, Fac Pharmaceut Sci, Resp Evaluat Sci Program, Vancouver, BC, Canada
[3] AstraZeneca, Gaithersburg, MD USA
[4] Univ Aberdeen, Div Appl Hlth Sci, Ctr Acad Primary Care, Aberdeen, Scotland
来源：
EUROPEAN RESPIRATORY JOURNAL | 2021年 / 58卷
关键词：
Treatments; Severe asthma; Asthma; -; management;
D O I：
10.1183/13993003.congress-2021.PA1113
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA1113
引用
收藏
页数：2
相关论文
共 49 条
  • [21] Long-term effectiveness of anti-IL4R therapy following suboptimal response to anti-IL5/5R therapy in severe eosinophilic asthma
    Gates, J.
    Fernandes, M.
    Hearn, A.
    Green, L.
    Thomson, L.
    Roxas, C.
    Lam, J.
    d'Ancona, G.
    Nanzer, A. M.
    Dhariwal, J.
    Jackson, D. J.
    THORAX, 2023, 78 (SUPPL_4) : A47 - A48
  • [22] Anti-IgE and Anti-IL5 Biologic Therapy in the Treatment of Nasal Polyposis: A Systematic Review and Meta-analysis
    Rivero, Alexander
    Liang, Jonathan
    ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 2017, 126 (11): : 739 - 747
  • [23] Dual Anti-IgE and Anti-IL5 Therapy in Treatment-Resistant Allergic Bronchopulmonary Aspergillosis: A Case Series
    Yenepalli, A.
    Diaz, L. V. L.
    Jiang, S.
    Lo, L.
    Eggert, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [24] Enose - Derived Response Clusters in Severe Asthmatics Treated With Anti-IL5/5R Biologics
    Dixey, P.
    Kermani, N. Zounemat
    Raby, K.
    Bhavsar, P. K.
    Chung, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [25] THE IMPACT OF ANTI-IL5/5R BIOLOGIC THERAPIES ON SPECIFIC DOMAINS OF THE ASTHMA CONTROL QUESTIONNAIRE
    Rykova, E.
    Hearn, A. P.
    Kavanagh, J.
    d'Ancona, G.
    Fernandes, M.
    Green, L.
    Roxas, C.
    Thomson, L.
    Dhariwal, J.
    Nanzer, A. M.
    Jackson, D. J.
    THORAX, 2021, 76 : A147 - A148
  • [26] THE RELATIONSHIP BETWEEN FENO AND RESPONSE TO ANTI-IL5/5R BIOLOGIC THERAPIES IN SEVERE EOSINOPHILIC ASTHMA
    Hearn, A. P.
    Kavanagh, J.
    d'Ancona, G.
    Fernandes, M.
    Green, L.
    Roxas, C.
    Thomson, L.
    Dhariwal, J.
    Nanzer, A. M.
    Jackson, D. J.
    THORAX, 2021, 76 : A143 - A144
  • [27] Identification of severe asthma patients eligible for anti-IL-5 or anti-IgE treatment: Findings from a Korean asthma cohort, COREA
    Lee, J.
    Kang, Y.
    Won, H.
    An, J.
    Kwon, H.
    Song, W.
    Cho, Y. S.
    Moon, H.
    Kim, T.
    ALLERGY, 2019, 74 : 293 - 293
  • [28] Identifying Asthma Patients Eligible for Anti-IL5 Treatment Using Electronic Health Records
    Yang, F.
    Lee, N.
    Thomson, N. C.
    Shepherd, M.
    Chaudhuri, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [29] Anti-IL5/IL5R switching between biologics in patients with severe eosinophilic asthma
    Yilmaz, Insu
    Cetin, Gulden Pacaci
    Arslan, Bahar
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (07): : 1935 - 1936
  • [30] Discrepancies between anti-Intereukin5 ( anti-IL5) starters from SHARP central registry and eligible patients in clinical trials
    Principe, S.
    Richards, L. B.
    Hashimoto, S.
    Kroes, J. A.
    Van Bragt, J. J.
    Vijverberg, S. J.
    Sont, J. K.
    Scichilone, N.
    Bieksiene, K.
    Brinke, A. T.
    Csoma, Z.
    Dahlen, B.
    Gemicioglu, B.
    Grisle, I
    Kuna, P.
    Lazic, Z.
    Mihaltan, F.
    Popovic-Grle, S.
    Skgrat, S.
    Van der Zee, A. Maitland
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
12345